 |
| 23-Apr-14 | Reiterated |
Oppenheimer |
Perform |
$121 → $122 |
|
| 21-Mar-14 | Reiterated |
Barclays |
Equal Weight |
$115 → $130 |
|
| 31-Jan-14 | Reiterated |
Argus |
Buy |
$130 → $135 |
|
| 20-Nov-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| 29-Aug-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| 27-Aug-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| 31-Jul-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| 24-Apr-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| 08-Apr-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| 25-Jan-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| 24-Jan-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| 12-Sep-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| 10-Sep-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
| 02-Aug-12 | Downgrade |
Argus |
Buy → Hold |
|
|
| 15-Mar-12 | Resumed |
Stifel Nicolaus |
Hold |
|
|
| 09-Feb-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 09-Sep-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 10-May-11 | Reiterated |
MP Advisors |
Outperform |
$63 → $65 |
|
| 25-Apr-11 | Reiterated |
Stifel Nicolaus |
Buy |
$70 → $68 |
|
|
|
| 24-Apr-14 02:00PM | ResMed Posts In-line Earnings but Misses on Revs Zacks |
| 10:29AM | Biotech Falls Again as Celgene Suffers at Barrons.com |
| 09:14AM | Stock Market News for April 24, 2014 Zacks |
| 23-Apr-14 08:18PM | Why Intuitive Surgical, Netflix, and Amgen Are Today's 3 Worst Stocks at Motley Fool -5.01% |
| 07:02PM | Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet PR Newswire |
| 06:32PM | 3 Reasons Celgene Will Bounce Back This Year at Motley Fool |
| 05:20PM | Encouraging Results from Pfizer's Xeljanz Zacks |
| 04:52PM | This company just had the best new drug launch of all-time Talking Numbers |
| 04:27PM | Amgen Revenue Misses Analysts Estimates on Enbrel Sales at Bloomberg |
| 04:27PM | [video] The Top Ten Stocks for April 23 at Bloomberg |
| 04:22PM | Stocks End Six-Day Win Streak As Techs Sell Off at Investor's Business Daily |
| 03:35PM | Why Investors Are Not Chasing Gilead Endlessly Higher at 24/7 Wall St. |
| 03:10PM | Earnings from Gilead and Amgen Put These ETFs in Focus Zacks |
| 12:12PM | Stocks slip as earnings, disappointing home sales weighed at CNBC |
| 12:04PM | Market Hustle: Stocks Slip After Weak China Data, Drop in U.S. Home Sales at TheStreet |
| 11:01AM | Why Amgen (AMGN) Stock Is Down Today at TheStreet |
| 10:28AM | Wall Street edges lower following six-day S&P rally Reuters |
| 10:07AM | Should Amgen Break Itself Up? at Forbes |
| 10:02AM | Amgen (AMGN) Showing Signs Of Being A Roof Leaker at TheStreet |
| 09:08AM | [video] Cramer: Gilead crux of health care in US at CNBC |
| 08:55AM | Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles at Investor's Business Daily |
| 08:40AM | Amgen's Q1 Earnings Decline Y/Y Zacks |
| 08:36AM | Alnylam Strikes Back: Comments From CEO John Maraganore at Forbes |
| 07:53AM | Amgen weakness a buying opportunity, says Cowen theflyonthewall.com |
| 05:00AM | 'Fast Money' Recap: Riding the Momentum at TheStreet |
| 02:17AM | Centene (CNC) Soars: Stock Adds 12.2% in Session Zacks |
| 12:41AM | Amgen's CEO Discusses Q1 2014 Results - Earnings Call Transcript Seeking Alpha |
| 22-Apr-14 10:05PM | Amgen Posts Lower-Than-Expected Earnings at New York Times |
| 10:05PM | Amgen Posts Lower-Than-Expected Earnings at New York Times |
| 07:13PM | Amgen misses 1Q views as higher costs cut profit AP |
| 07:09PM | [$$] Amgen Profit Falls 25% at The Wall Street Journal |
| 06:34PM | New Drugs Help Drive Amgen's Operating Income Up 18% in Q1 at Motley Fool |
| 06:02PM | Amgen profit falls on inventory draw downs; sales disappoint Reuters |
| 05:55PM | Gilead shares climb; AT&T, Amgen shares fall at MarketWatch |
| 05:23PM | Amgen misses 1Q views as higher costs cut profit AP |
| 05:15PM | Amgen Earnings Call scheduled for 5:15 pm ET today CCBN |
| 05:05PM | Gilead shares climb; AT&T, Amgen shares fall at MarketWatch |
| 05:04PM | Amgen earnings down 25% as costs rise at MarketWatch |
| 04:50PM | The closest thing to a sure thing for you and your money at MarketWatch |
| 04:48PM | An Earnings Tale of Two Biotechs Gilead vs. Amgen 24/7 Wall St. |
| 04:40PM | Amgen earnings down 25% as costs rise at MarketWatch |
| 04:39PM | Amgen misses 1Q views as higher costs cut profit AP |
| 04:34PM | [$$] Amgen Profit Falls 25% at The Wall Street Journal |
| 04:32PM | Amgen says total product sales declined 9% sequentially in Q1 at theflyonthewall.com |
| 04:26PM | Amgen Falls as Earnings, Revenue Disappoint at Barrons.com |
| 04:24PM | Earnings and big pharma deals drive stocks up Hot Stock Minute |
| 04:15PM | AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:13PM | Amgen revenue misses analyst estimates at Los Angeles Times |
| 04:13PM | Amgen profit falls on costs, disappointing sales Reuters |
| 04:09PM | Amgen earnings, sales come in below estimates at MarketWatch |
| 04:06PM | [video] Amgen Q1 earnings miss at CNBC |
| 04:04PM | Amgen Revenue Misses Analysts Estimates on Enbrel Sales at Bloomberg |
| 04:03PM | Amgen's First Quarter 2014 Revenues Increased 7 Percent To $4.5 Billion PR Newswire |
| 03:52PM | AT&T, Yum Brands set for after-hours action at MarketWatch |
| 03:45PM | Sarepta Soars on Eteplirsen Submission Plans Zacks |
| 02:35PM | Earnings Preview: Amgen's timeline for Evolocumab will be in focus at theflyonthewall.com |
| 02:12PM | AT&T, Yum Brands set for after-hours action at MarketWatch |
| 01:07PM | [video] Biggest biotech players at CNBC |
| 08:47AM | Amgen Versus Celgene: Value/Growth Face Off at Seeking Alpha |
| 07:34AM | Amgen Earnings Call scheduled for 5:15 pm ET today CCBN |
| 07:07AM | Q1 2014 Amgen Earnings Release - After Market Close CCBN |
| 03:51AM | Pfizer, AstraZeneca Are Ripe for Pharma Deal: Real M&A Bloomberg |
| 03:51AM | Pfizer, AstraZeneca Are Ripe for Pharma Deal Alone or Together Bloomberg |
| 21-Apr-14 06:34PM | What to Watch for in Biotech Earnings This Week at Motley Fool |
| 05:41PM | Value stocks to stay in vogue, as momentum fades at CNBC |
| 05:20PM | Will Amgen (AMGN) Miss This Earnings Season? Zacks |
| 04:48PM | Retail Investors Should Be Doing Valuations On Their Biotechs - The Market Is at Seeking Alpha |
| 03:54PM | [video] Earnings crystal ball at CNBC |
| 02:34PM | Biotech Is Not A Popping Bubble: Buy The Dip While You Can at Seeking Alpha |
| 02:09PM | Another Technical Look at the Big Biotech ETF ETF Trends |
| 12:20PM | Can Gilead's Sovaldi rescue biotech? at CNBC |
| 18-Apr-14 12:12PM | Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings at Investor's Business Daily |
| 17-Apr-14 05:03PM | FDA Grants Fast Track Status To Amgen Heart Failure Drug at Forbes |
| 04:10PM | Emergent BioSolutions Gains on Trial News Zacks |
| 04:05PM | Amgen Announces Webcast of 2014 First Quarter Financial Results PR Newswire |
| 02:34PM | A Real Dividend Growth Machine: Q1 2014 Review at Seeking Alpha |
| 01:22PM | [video] Kudlow: Two economic cycles at CNBC |
| 09:32AM | Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc. at Motley Fool |
| 16-Apr-14 03:10PM | Dynavax Starts Phase III Study on Heplisav-B Zacks |
| 05:00AM | 'Fast Money' Recap: Impressed by Yahoo! at TheStreet |
| 15-Apr-14 04:23PM | Nasdaq rides biggest trading rollercoaster in five years at CNBC |
| 04:20PM | Encouraging Results from Lexicon Candidate Zacks |
| 02:03PM | Capitulation or correction? Nasdaq nears 10% drop at CNBC |
| 01:19PM | Another Earnings Beat from J&J, View Up Zacks |
| 12:40PM | [video] Love biotech on correction: Trader at CNBC |
| 12:37PM | [video] Top biotech analyst forecasts bottom at CNBC |
| 06:49AM | Ambit Biosciences Slumps: AMBI Falls 13.0% in Session Zacks |
| 05:00AM | 'Fast Money' Recap: Long on Financials at TheStreet |
| 14-Apr-14 06:14PM | Amgen's Conundrum at Motley Fool |
| 03:30PM | Positive Results on Intercept Pharma's OCA Zacks |
| 10:30AM | Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks |
| 10:05AM | Momentum Investing: When Leaders Become Laggards at Barrons.com |
| 07:43AM | [video] Pro picks Gannett, Amgen & more at CNBC |
| 12-Apr-14 12:01AM | [$$] The Highfliers Are Still Too High at Barrons.com |
| 11-Apr-14 02:32PM | Are Celgene and Amgen Undervalued By the Market? at Motley Fool |
| 08:42AM | [video] Here's what's pushing biotech lower: Expert at CNBC |
| 08:32AM | 3 Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha |
| 12:06AM | This is the make-or-break level for biotech Talking Numbers |
| 10-Apr-14 03:39PM | Gilead Announces Encouraging Sovaldi Data Zacks |
| 03:37PM | Biotech: Like Lambs to the Slaughter at Barrons.com |
|
|
| Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| de Carbonnel Francois | Director | Mar 06 | Option Exercise | 54.44 | 10,000 | 544,350 | 25,364 | Mar 07 05:23 PM | | de Carbonnel Francois | Director | Mar 06 | Sale | 126.69 | 1,000 | 126,690 | 18,343 | Mar 07 05:23 PM | | BALTIMORE DAVID | Director | Feb 26 | Option Exercise | 62.55 | 5,000 | 312,750 | 31,879 | Feb 26 08:28 PM | | HENDERSON REBECCA M | Director | Feb 13 | Option Exercise | 62.41 | 20,000 | 1,248,160 | 25,549 | Feb 14 04:34 PM | | HENDERSON REBECCA M | Director | Feb 13 | Sale | 123.53 | 20,000 | 2,470,680 | 5,549 | Feb 14 04:34 PM | | Bradway Robert A | Chairman, CEO and President | Feb 12 | Option Exercise | 62.55 | 65,000 | 4,065,750 | 216,040 | Feb 14 04:19 PM | | AMGEN INC | 10% Owner | Dec 17 | Buy | 7.00 | 272,142 | 1,904,994 | 541,399 | Dec 18 06:09 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Option Exercise | 58.43 | 18,000 | 1,051,740 | 59,133 | Sep 05 07:33 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Sale | 112.76 | 18,000 | 2,029,768 | 34,851 | Sep 05 07:33 PM | | BALTIMORE DAVID | Director | Aug 28 | Sale | 109.66 | 4,582 | 502,462 | 27,789 | Aug 30 05:36 PM | | Amgen Ventures LLC | 10% Owner | Jun 05 | Buy | 15.00 | 16,666 | 249,990 | 334,126 | Jun 05 04:01 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Option Exercise | 54.62 | 6,130 | 334,791 | 22,863 | May 24 05:18 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Sale | 104.78 | 6,130 | 642,296 | 16,733 | May 24 05:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Option Exercise | 50.44 | 6,000 | 302,640 | 46,956 | May 21 08:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Sale | 103.28 | 6,000 | 619,681 | 34,851 | May 21 08:18 PM | | HENDERSON REBECCA M | Director | May 17 | Option Exercise | 55.76 | 7,000 | 390,310 | 13,898 | May 20 07:15 PM | | HENDERSON REBECCA M | Director | May 17 | Sale | 105.72 | 8,421 | 890,300 | 5,477 | May 20 07:15 PM | | Patton Cynthia M | SVP & CCO | May 16 | Option Exercise | 54.58 | 3,544 | 193,437 | 18,986 | May 17 05:42 PM | | Patton Cynthia M | SVP & CCO | May 16 | Sale | 105.01 | 3,544 | 372,148 | 15,442 | May 17 05:42 PM | | BIONDI FRANK | Director | May 14 | Option Exercise | 56.50 | 10,000 | 564,950 | 39,780 | May 16 05:38 PM | | PELHAM JUDITH C | Director | May 14 | Option Exercise | 55.47 | 25,000 | 1,386,650 | 48,149 | May 16 05:42 PM | | PELHAM JUDITH C | Director | May 14 | Sale | 108.25 | 25,000 | 2,706,165 | 23,149 | May 16 05:42 PM | | BIONDI FRANK | Director | May 14 | Sale | 108.43 | 10,000 | 1,084,318 | 29,780 | May 16 05:38 PM | | de Carbonnel Francois | Director | Apr 30 | Option Exercise | 54.74 | 10,000 | 547,400 | 21,930 | May 02 06:26 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Option Exercise | 50.44 | 10,000 | 504,400 | 64,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Sale | 107.02 | 10,000 | 1,070,191 | 54,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Option Exercise | 58.43 | 10,000 | 584,300 | 66,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Sale | 107.99 | 10,000 | 1,079,872 | 56,077 | Apr 30 05:21 PM |
|
|
|
|
|
|
